JP2024517381A5 - - Google Patents

Info

Publication number
JP2024517381A5
JP2024517381A5 JP2023562257A JP2023562257A JP2024517381A5 JP 2024517381 A5 JP2024517381 A5 JP 2024517381A5 JP 2023562257 A JP2023562257 A JP 2023562257A JP 2023562257 A JP2023562257 A JP 2023562257A JP 2024517381 A5 JP2024517381 A5 JP 2024517381A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
pharmaceutical product
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517381A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/086143 external-priority patent/WO2022218264A1/en
Publication of JP2024517381A publication Critical patent/JP2024517381A/ja
Publication of JP2024517381A5 publication Critical patent/JP2024517381A5/ja
Pending legal-status Critical Current

Links

JP2023562257A 2021-04-11 2022-04-11 がんを治療するための併用療法 Pending JP2024517381A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163173479P 2021-04-11 2021-04-11
US63/173,479 2021-04-11
US202263300567P 2022-01-18 2022-01-18
US63/300,567 2022-01-18
PCT/CN2022/086143 WO2022218264A1 (en) 2021-04-11 2022-04-11 Combination therapies for treating cancer

Publications (2)

Publication Number Publication Date
JP2024517381A JP2024517381A (ja) 2024-04-22
JP2024517381A5 true JP2024517381A5 (cg-RX-API-DMAC7.html) 2025-04-14

Family

ID=83640122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562257A Pending JP2024517381A (ja) 2021-04-11 2022-04-11 がんを治療するための併用療法

Country Status (4)

Country Link
US (1) US20240209092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323001A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517381A (cg-RX-API-DMAC7.html)
WO (1) WO2022218264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4583981A2 (en) * 2022-09-09 2025-07-16 Adagene Pte. Ltd. Activatable anti-ctla4 antibodies for treating cancer
WO2024216179A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Methods for treating cancer using activatable anti-ctla4 antibody in combination with pembrolizumab

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200005662A (ko) * 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
WO2019036855A1 (en) * 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CA3122773A1 (en) * 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2018508483A5 (cg-RX-API-DMAC7.html)
JP2019513701A5 (cg-RX-API-DMAC7.html)
US10174117B2 (en) Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2018529312A5 (cg-RX-API-DMAC7.html)
EP4480967A1 (en) Development and use of novel immunomodulator
FI3802598T3 (fi) Dll3/cd3:a sitovia proteiineja syövän hoitamiseksi
FI3625259T3 (fi) Anti-sirp-alfa vasta-aineet
HRP20240626T1 (hr) Bispecifična antitijela protiv ceacam5 i cd3
JP2019502712A5 (cg-RX-API-DMAC7.html)
JP2020514310A5 (cg-RX-API-DMAC7.html)
JP2017506217A5 (cg-RX-API-DMAC7.html)
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2022546454A5 (cg-RX-API-DMAC7.html)
JP2022169589A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2024517381A5 (cg-RX-API-DMAC7.html)
JP2022548078A5 (cg-RX-API-DMAC7.html)
JP2013513383A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)
RU2012131411A (ru) АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ
JPWO2022270612A5 (cg-RX-API-DMAC7.html)
JP2025507817A5 (cg-RX-API-DMAC7.html)
JP2019524706A5 (cg-RX-API-DMAC7.html)
JP2021531255A5 (cg-RX-API-DMAC7.html)